Scientific publications and reach in the field have shown already that post-injury angiogenesis and vascular remodeling ...

In a live event, Ganesh V. Raj, MD, PhD, discussed the drug-drug interactions and outcomes by disease volumes across ARPI ...

Marlise R. Luskin, MD, MSCE, discussed treatment options for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and ...

Panelists discuss how the term "late-line" in relapsed/refractory multiple myeloma typically refers to patients who have progressed through multiple previous treatment regimens, indicating a more ...

Researchers identified three new all-oral drug regimens that include at least one of two new drugs for treatment of rifampin-resistant tuberculosis, according to a study. The study tested five all ...

Results show similar levels of virus undetectability in patients on ibalizumab-containing regimens as in controls, despite greater baseline ...

EBRT with or without STAD showed similar 15-year PCSS and OS rates in IRPC patients, with high PSA failure rates observed. Multivariate analysis indicated greater side effects in the STAD group ...

Researchers sought to determine whether CAR-T therapy with ide-cel would be effective in patients with triple-class–exposed relapsed/refractory MM.

A synthetic chronogenetic gene circuit for programmed circadian drug delivery - ...

This systematic review aimed to quantify maternal adverse effects attributed to treatment, assess how adverse effects vary according to different regimens, and explore women's experiences with ...